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Abstract: Endothelial activation and inﬂ  ammation are important mediators of accelerated 
atherogenesis and consequent increased cardiovascular morbidity in obstructive sleep apnea 
(OSA). Repetitive episodes of hypoxia/reoxygenation associated with transient cessation of 
breathing during sleep in OSA resemble ischemia/reperfusion injury and may be the main culprit 
underlying endothelial dysfunction in OSA. Additional factors such as repetitive arousals 
resulting in sleep fragmentation and deprivation and individual genetic suseptibility to vascular 
manifestations of OSA contribute to impaired endothelial function in OSA. The present 
review focuses on possible mechanisms that underlie endothelial activation and inﬂ  ammation 
in OSA.
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Introduction
Obstructive sleep apnea (OSA), a condition that affects up to a quarter of the 
American adult population, remains largely unrecognized, and less than 5% of all 
OSA patients receive treatment (Young et al 1993, 1997). Raising awareness among 
medical practitioners, and cardiologists in particular, about the high prevalence of 
unrecognized OSA is of great importance considering that OSA is an independent 
and potentially reversible risk factor for hypertension, myocardial ischemia and stroke 
(Peker et al 1999; Peppard et al 2000; Yaggi et al 2005; Yumino et al 2007). Increased 
cardiovascular morbidity in patients with untreated OSA is attributed to accelerated 
atherosclerosis (Kato et al 2000; Ip et al 2004; Drager et al 2005, 2007; Minoguchi 
et al 2005; Saletu et al 2006; Savransky et al 2007). The initial stimulus that triggers 
accelerated atherogenesis has not been deﬁ  nitively established.
Impaired endothelial function plays an important role in the development of 
cardiovascular manifestations of OSA. Normal endothelium regulates vasomotor tone 
and preserves inﬂ  ammatory and coagulation homeostasis (Aird 2007). These functions 
are altered in patients with OSA compared with healthy subjects (Carlson et al 1996; 
Ohga et al 1999; Kato et al 2000; Dyugovskaya et al 2002, 2005; Ip et al 2004; Nieto 
et al 2004; Jelic et al 2008). Reduced numbers of endothelial progenitor cells and 
increased endothelial cell apoptosis in untreated OSA indicate impaired endothelial 
repair capacity (El Solh et al 2007, 2008; Jelic et al 2008; Martin et al 2008). In 
addition, increased sympathetic nervous activity may also contribute to cardiovascular 
morbidity in OSA (Narkiewicz and Somers 2003; Maser et al 2008). However, the 
reversibility of autonomic alterations with OSA-speciﬁ  c therapy remains controversial 
(Narkiewicz et al 1999; Esler and Eikelis 2006; Mills et al 2006).
Repetitive hypoxia/reoxygenation associated with transient cessation of breathing 
during apneas and hypopneas is considered the main culprit for the impairment of 
endothelial function in OSA. Repetitive arousals resulting in sleep fragmentation 
and chronic sleep deprivation may also contribute to vascular dysfunction in OSA. Vascular Health and Risk Management 2008:4(6) 1328
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Lastly, individual genetic susceptibility may play a role in 
development of cardiovascular manifestations of untreated 
OSA. The present review will focus on possible mechanisms 
of endothelial dysfunction in OSA.
Repetitive hypoxia/reoxygenation
Repetitive hypoxia/reoxygenation during transient cessation 
of breathing as occurs in OSA resembles ischemia/
reperfusion injury. Although perfusion remains intact during 
obstructive events in OSA, alterations involving generation 
of reactive oxygen species, inﬂ  ammation and reduced nitric 
oxide (NO) availability are similar to those observed in 
models of ischemia-reperfusion (Liao et al 1995; Wang et al 
1996; Kato et al 2000; Laursen et al 2001; Dyugovskaya 
et al 2002; Takemoto et al 2002; Kuzkaya et al 2003; Ip et al 
2004; Minoguchi et al 2005; Antoniades et al 2006).
Endothelial nitric oxide availability
Indirect evidence such as impaired ﬂ  ow-mediated brachial 
arterial dilation and decreased circulating NO levels 
measured by serum nitrite/nitrate suggest reduced NO 
availability in OSA patients (Kato et al 2000; Ip et al 2000, 
2004; Noda et al 2007). Plasma levels of an endogenous 
inhibitor of endothelial nitric oxide synthase (eNOS) are 
increased and correlate inversely with flow-mediated 
dilation in patients with untreated OSA (Ohike et al 2005). 
Plasma levels of L-arginine, the substrate for NO production, 
increase after a single night of CPAP therapy in patients 
with OSA (Lavie et al 2003). Decreased eNOS activity and 
increased nitrotyrosine production, a byproduct of nitric 
oxide degradation, in freshly harvested venous endothelial 
cells provide direct evidence that nitric oxide bioavailability 
is reduced in OSA patients without overt cardiovascular 
disease (Jelic et al 2008).
Expression and activity of eNOS, a main source of basal 
endothelial NO, have been reported to be upregulated (Arnet 
et al 1996; Le Cras et al 1998; Coulet et al 2003; Shirai et al 
2003), downregulated (McQuillan et al 1994; Liao et al 
1995; Phelan and Faller 1996; Laufs et al 1997; Toporsian 
et al 2000; Takemoto et al 2002), or unchanged (Murata et al 
2001; Tahawi et al 2007) in various experimental models of 
hypoxia and repetitive hypoxia/reoxygenation. Contradictory 
reports of eNOS expression and activity appear to be due to 
temporal variations in experimental hypoxemic conditions, 
and differences in the species and vascular bed from which 
endothelial cells were derived. Long-term intermittent 
hypoxia that mimicked OSA, administered in 30-second 
cycles for 6–8 hours daily for 35 days, resulted in elevated 
diurnal resting mean arterial blood pressure in rats (Fletcher 
et al 1992; Tahawi et al 2007). Attenuated vasodilation 
in response to acetylcholine, a vasodilator that stimulates 
endothelial release of NO, and greater vasoconstriction with 
the NOS inhibitor NG-nitro-L-arginine methyl ester in rats 
exposed to long-term hypoxia/reoxygenation compared with 
controls, suggest decreased NO availability (Tahawi et al 
2007). After prolonged hypoxia, eNOS activity is reduced 
(Kiss et al 1998; Takemoto et al 2002), resulting in impaired 
vascular reactivity (Danton et al 2002).
Several mechanisms of hypoxia-induced eNOS down-
regulation have been proposed (Coulet et al 2003; Tai et al 
2004). On a transcriptional level, hypoxia-induced activation 
of hypoxia inducible factor-2 initially upregulates eNOS 
mRNA followed by a prolonged decrease in eNOS mRNA 
level (Coulet et al 2003). On a post-transcriptional level, 
hypoxia destabilizes eNOS mRNA, in part via the Rho 
kinase pathway in human venous and pulmonary artery 
endothelial cells (Takemoto et al 2002). Hypoxia increases 
arginase II activity in endothelial cells, which degrades 
L-arginine, an essential substrate for NO production by 
eNOS (Clarkson et al 2005). Oxidation of the eNOS cofactor 
tetrahydrobiopterin (BH4) by reactive oxygen species such as 
peroxynitrite appears to be an important mechanism linking 
oxidative stress to endothelial dysfunction (Kuzkaya et al 
2003; Antoniades et al 2006). Decreased BH4 availabil-
ity promotes superoxide production by eNOS, an altered 
enzyme state labeled “uncoupling” (Vasquez-Vivar et al 
1998; Xia et al 1998). Exposure to hypoxia for 24 hours leads 
to a time-dependent decrease in eNOS activator heat shock 
protein 90 that correlates with a decrease in eNOS activity 
in pulmonary artery endothelial cells (Garcia-Cardena et al 
1998; Su and Block 2000). In contrast to short-term exposure 
to oxidative stress, prolonged oxidative stress as observed 
in untreated OSA reduces eNOS activity by suppressing its 
phosphorylation (Thomas et al 2002; Tanaka et al 2005). 
Reduced NO availability results in endothelial dysfunction 
and thereby increases the risk for vascular diseases in 
patients with OSA.
Endothelial and systemic inﬂ  ammation
Elevated levels of plasma C-reactive protein (Shamsuzzaman 
et al 2002), leukocyte superoxide (Schulz et al 2000; 
Dyugovskaya et al 2002) and soluble adhesion molecules 
(Ohga et al 1999) suggest the presence of chronic 
systemic inﬂ  ammation in OSA patients. Upregulation of 
cyclooxygenase-2 (COX-2) and inducible NOS in venous 
endothelial cells harvested from patients with untreated Vascular Health and Risk Management 2008:4(6) 1329
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OSA provides direct evidence of vascular inﬂ  ammation in 
OSA (Jelic et al 2008).
Accumulation and adhesion of circulating leukocytes to 
the vascular endothelium lead to vessel inﬂ  ammation and 
progression of atherosclerosis (Price and Loscalzo 1999; 
Aird 2007). Monocyte expression of the adhesion molecules 
CD15 and CD11c is increased in patients with OSA 
compared with controls matched for age and cardiovascular 
comorbidities, although not BMI (Dyugovskaya et al 
2002). Enhanced oxidative stress and adhesion to cultured 
endothelial cells in monocytes collected in the morning from 
OSA patients suggest an adverse effect of OSA on diurnal 
vascular proinﬂ  ammatory/antiinﬂ  ammatory homeostasis 
(Dyugovskaya et al 2002). Lymphocytic production of 
interleukin-4 (IL-4), a proinﬂ  ammatory cytokine, is greater, 
while production of IL-10, a potent antiinflammatory 
cytokine, is decreased in otherwise healthy patients with 
moderate to severe OSA, compared with subjects with an 
AHI 10/h (Dyugovskaya et al 2005).
Hypoxia/reoxygenation increases COX-2 gene and 
protein expression in endothelial cells in vivo and in 
vitro (Domoki et al 1999; Li et al 2003; Wu et al 2003). 
Although COX-2 is widely accepted as a proinﬂ  ammatory 
agonist, its upregulation can be cardioprotective in ischemia-
reperfusion injury (Bolli et al 2002). In addition, the use 
of COX-2 inhibitors may result in an increased incidence 
of cardiovascular events (Antman et al 2005). COX-2 
appears to have a dual role in inflammation: initially 
inducing the inflammatory process and later aiding its 
resolution (Gilroy et al 1999). Upregulation of COX-2 in 
OSA may result in increased oxidative stress caused by 
superoxide production and increased vasoconstrictor and/or 
inﬂ  ammatory prostanoid production leading to increased 
platelet activation and endothelial dysfunction (Antman 
et al 2005). Alternatively, induction of endothelial COX-2 in 
OSA patients may be a defense mechanism against repetitive 
hypoxia/reoxygenation.
Experimental models of repetitive hypoxia/reoxygenation 
that mimic OSA suggest that the proinflammatory 
transcription factor NF-κB is activated selectively over the 
hypoxia-inducible factor-1 (HIF-1) adaptive pathway in 
cultured endothelial cells, suggesting a maladaptive response 
to hypoxic stimulus in OSA (Ryan et al 2005; Greenberg 
et al 2006). NF-κB upregulates several proinﬂ  ammatory 
genes, including tumor necrosis factor-alpha (TNF-α) and 
IL-6 (Williams and Scharf 2007). Circulating levels of IL-6 
and TNF-α are consistently elevated in patients with OSA, 
independently from central obesity (Alam et al 2007). The 
initial sensing and signaling event for NF-κB activation 
remains unknown since it does not appear to be inﬂ  uenced 
by oxidative stress (Hayakawa et al 2003). In contrast, other 
investigators reported elevated levels of vascular endothelial 
growth factor (VEGF) and nocturnal erythropoietin, both 
mediated by the HIF-1 pathway, suggesting HIF-1 activation 
in patients with OSA (Lavie et al 2002; Winnicki et al 
2004). Since hypertension is associated with elevated VEGF 
concentrations, these discrepancies regarding activation 
of the adaptive HIF-1 pathway in OSA may be due to the 
coexistence of hypertension in some OSA patients (Valipour 
et al 2004). Alternatively, similar to COX-2 upregulation, 
VEGF upregulation may be an adaptive response to repetitive 
hypoxia/reoxygenation in OSA (Shweiki et al 1992; Forsythe 
et al 1996; Marti et al 1998; Dor et al 2001).
In summary, endothelial proinﬂ  ammatory/antiinﬂ  ammatory 
homeostasis is shifted toward vascular inflammation in 
patients with untreated OSA.
Endothelial oxidative stress
Recent studies have demonstrated increased lipid peroxidation 
and generation of reactive oxygen species (ROS) by blood 
cells in OSA (Barcelo et al 2000; Christou et al 2003a, 2003b; 
Lavie et al 2004; Jung et al 2005; Yamauchi et al 2005; Tan 
et al 2006). Vasoreactivity in OSA can be improved by 
antioxidants such as ascorbate and allopurinol, suggesting 
that oxidative stress contributes to endothelial dysfunction 
(El Solh et al 2006; Grebe et al 2006). The reoxygenation/
reperfusion phase of the hypoxia/reoxygenation cycle appears 
to promote production of ROS leading to oxidative stress 
in OSA (Dean and Wilcox 1993; Prabhakar 2002; Lavie 
2003). Short-term intermittent hypoxia enhances cardiac 
susceptibility to ischemia/reperfusion injury in mice whereas 
longer exposure does not, suggesting temporal variation in 
response to oxidative stress (Park and Suzuki 2007). Repetitive 
episodes of hypoxia/reoxygenation increase production of 
reactive oxygen species in experimental models (McQuillan 
et al 1994; Liao et al 1995). Exposure of lean rodents to 
repetitive hypoxia/reoxygenation increases lipid peroxidation 
and decreases tissue-scavenging mechanisms in both heart 
and brain tissues (Xu et al 2004; Chen et al 2005). Super-
oxide rapidly scavenges NO, generating peroxynitrate, a 
toxic metabolite that nitrosylates tyrosine residues, forming 
nitrotyrosine, a marker of oxidative stress (Knepler et al 
2001). Levels of circulating free nitrotyrosine are similar in 
patients with OSA and healthy subjects (Svatikova et al 2004). 
In contrast, expression of nitrotyrosine in endothelial cells 
harvested from otherwise healthy patients with OSA is greater Vascular Health and Risk Management 2008:4(6) 1330
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than controls, suggesting enhanced endothelial oxidative stress 
(Jelic et al 2008). Endothelial expression of nitrotyrosine 
more closely reﬂ  ects endothelial oxidative stress in OSA than 
levels of circulating free nitrotyrosine since the in vivo half-
life of nitrotyrosine is short, and its volume of distribution is 
20-fold greater than the plasma volume indicating its extensive 
distribution in the extravascular compartment (Tabrizi-Fard 
et al 1999). As endothelial oxidative stress increases and 
fewer cofactors are available for nitric oxide synthesis, eNOS 
preferentially promotes superoxide production, thereby 
perpetuating a vicious cycle of endothelial injury (Vasquez-
Vivar et al 1998; Xia et al 1998; Laursen et al 2001).
Repetitive hypoxia/reoxygenation promotes endothelial 
apoptosis by activating cell death receptors and mitochondria-
dependent apoptotic pathways (Dhar-Mascareno et al 
2005; Zhang et al 2005). Exposure of rat aortic rings to 
increasing concentrations of isolated endothelial apoptotic 
microparticles derived from cultured endothelial cells or 
patients with myocardial ischemia alters endothelium-
dependent vasodilation and nitric oxide production while 
simultaneously increasing superoxide production (Boulanger 
et al 2001; Brodsky et al 2004). Furthermore, increased 
concentrations of endothelial apoptotic microparticles impair 
angiogenesis in vitro (Brodsky et al 2004).
Thus, repetitive hypoxia/reoxygenation as observed in 
OSA adversely impacts endothelial function by promoting 
oxidative stress and inﬂ  ammation, and reducing nitric oxide 
availability.
Sleep fragmentation 
and deprivation
Chronic sleep deprivation is associated with a 50% decline 
in endothelium-dependent vasodilation in healthy subjects 
suggesting reduced NO availability (Takase et al 2004). 
Levels of pro-inﬂ  ammatory markers such as C-reactive 
protein (CRP), IL-6, and TNF-α are elevated after partial and 
sustained sleep deprivation in healthy subjects (Meier-Ewert 
et al 2004; Vgontzas et al 2004; Irwin et al 2006; Haack 
et al 2007). Levels of soluble TNF-α receptor 1 and IL-6 
are elevated in healthy men after 4 days of sustained sleep 
deprivation, suggesting a role for sleep deprivation as a 
pro-inﬂ  ammatory stimulus (Shearer et al 2001).
Sleep deprivation may alter coagulation homeostasis. 
Elevated levels of plasma D-dimer are associated with 
OSA
Hypoxia/reoxygenation Sleep deprivation
↓Nitric oxide availability
↑Inflammation
↑Oxidative stress
↑Apoptosis
Genetic susceptibility
↑Cardiovascular risk
Endothelial
dysfunction
Figure 1 Intermediary mechanisms that mediate increased cardiovascular risk in obstructive sleep apnea (OSA). Repetitive hypoxia/reoxygenation associated with transient 
cessation of breathing while asleep promotes endothelial dysfunction in patients with OSA by increasing vascular inﬂ  ammation, oxidative stress and apoptosis while reducing 
nitric oxide availability. Sleep fragmentation and deprivation resulting from repetitive arousals during sleep compound the effects of hypoxia/reoxygenation injury by independently 
promoting vascular inﬂ  ammation. Genetic susceptibility may contribute to cardiovascular risk associated with OSA.Vascular Health and Risk Management 2008:4(6) 1331
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increased awake time after sleep onset in elderly subjects 
(Mausbach et al 2006; von Kanel et al 2006). Arousal index 
is correlated with plasma levels of von Willebrand’s factor, a 
mediator of platelet adhesion (von Kanel et al 2007). Wake 
after sleep onset time is correlated with levels of soluble 
tissue factor, an initiator of the coagulation cascade, after 
adjustment for AHI (von Kanel et al 2007).
Based on available evidence, sleep deprivation alone does 
not appear to promote oxidative stress. Sleep deprivation does 
not affect oxidant production, antioxidant enzyme activity, 
lipid peroxidation or protein oxidation in brain, liver, and 
skeletal muscle in a rat model (Gopalakrishnan et al 2004).
Chronic sleep deprivation is associated with greater 
prevalence of obesity that might itself increase cardiovascular 
risk in OSA. Sleep fragmentation, assessed with actigraphy, is 
associated with higher BMI and risk of obesity in community-
dwelling elderly (van de Berg et al 2008). Acute partial sleep 
deprivation reduces levels of leptin, a hormone regulating 
satiety and energy homeostasis, elevates levels of ghrelin, a 
hormone associated with appetite, and increases subjective 
sensation of hunger, creating a weight-gaining phenotype in 
healthy subjects (Spiegel et al 2004). Compared with longer 
sleep duration, self-reported sleep duration of 5 hours was 
associated with incident diabetes in 8992 subjects followed 
over 8–10 years (odds ratio = 1.5) (Gangwisch et al 2007). Self-
reported reduced sleep duration in 70,000 participants in the 
Nurses Health Study was associated with increased cardiovas-
cular risk over a 10-year period after adjustment for age, snoring 
and BMI (Ayas et al 2003). Acute sleep deprivation of healthy 
young men and women is associated with increased p-wave 
dispersion on electrocardiography, an electrophysiologic 
marker for the prediction of paroxysmal atrial ﬁ  brillation 
(Dilaveris et al 1998; Sari et al 2008). In addition, OSA itself 
has been associated with increased p-wave dispersion and 
incidence of atrial ﬁ  brillation (Gami et al 2004; Can et al 2008). 
Sustained sleep deprivation for 36 h increased sympathetic and 
decreased parasympathetic activity as measured by heart rate 
and blood pressure variability (Zhong et al 2005). Sleep depri-
vation-induced elevated sympathetic activity may contribute 
to adverse cardiovascular outcomes in OSA.
In summary, chronic sleep deprivation associated 
with OSA may potentiate the adverse effects of hypoxia/
reoxygenation on cardiovascular function.
Genetic contributions
Genetic susceptibility for cardiovascular manifestations of 
OSA may be mediated by gene polymorphisms associated with 
regulation of body weight, lipid metabolism, inﬂ  ammatory 
response and autonomic vascular function (Keavney et al 
2000; Kadotani et al 2001; Palmer et al 2003; Gottlieb 
et al 2004; Riha et al 2005; Borgel et al 2006; Popko et al 
2007). OSA patients with and without coexistent coronary 
artery disease are more likely to have a family history of 
premature cardiovascular death than those without OSA, after 
adjustment for BMI (Gami et al 2007). In a murine model of 
OSA, genetic background determines both the pattern and 
magnitude of the chronotropic response to apnea (Iiyori et al 
2005). Apolipoprotein E epsilon4 (ApoE epsilon4) is a well-
known risk factor for cardiovascular disease (Song et al 2004; 
Bennett et al 2007). The APOE epsilon4 allele is associated 
with increased risk of OSA, particularly in individuals under 
age 65 (Kadotani et al 2001; Gottlieb et al 2004).
Along with male gender, obesity is the strongest risk 
factor for the development of OSA (Patel 2005). Obesity 
explains nearly 40% of the genetic heritability of OSA in 
a large cohort of 310 families with OSA (Patel et al 2008). 
Levels of ghrelin, a hormone associated with appetite, 
decline to near normal levels following short-term CPAP 
therapy in obese OSA patients without concomitant change 
in body weight, suggesting that OSA itself promotes ghrelin 
production (Harsch et al 2003).
The G-allele of a single nucleotide polymorphism in 
the pro-inﬂ  ammatory IL-6 gene is associated with 6-fold 
increased odds of having OSA after adjustment for obesity 
(Larkin et al 2008). Increased prevalence of the TNF-α 
(–308A) polymorphism, a genotype associated with increased 
production of the pro-inﬂ  ammatory cytokine TNF-α, in OSA 
patients compared with population controls may reﬂ  ect a 
propensity for enhanced inﬂ  ammatory response to repetitive 
hypoxia/reoxygenation and sleep deprivation associated with 
OSA (Wilson et al 1997; Riha et al 2005).
Reports of an association between angiotensin-converting 
enzyme (ACE) polymorphisms and OSA have been 
inconsistent. Treatment with an angiotensin II receptor 
blocker prevents elevation of blood pressure due to repetitive 
hypoxia/reoxygenation in an animal model of OSA (Fletcher 
et al 1999). The D allele and in particular the DD genotype 
of the ACE gene is associated with the development 
of hypertension and may confer an increased risk of 
cardiovascular disease (O’Donnell et al 1998; Bengtsson 
et al 1999; Keavney et al 2000). OSA increases the risk of 
hypertension, particularly in male carriers of the ACE gene 
D allele (Lin et al 2004; Boström et al 2007). However, other 
investigators reported no signiﬁ  cant correlation between 
AHI and ACE activity in OSA patients (Xiao et al 1999; 
Barcelo et al 2001).Vascular Health and Risk Management 2008:4(6) 1332
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Summary
Endothelial dysfunction and inflammation mediate 
the cardiovascular manifestations of OSA. Repetitive 
hypoxia/reoxygenation, as observed in OSA, adversely 
impacts endothelial function by promoting oxidative stress 
and inﬂ  ammation, and reducing NO availability. Sleep 
fragmentation and deprivation may potentiate hypoxia/
reoxygenation injury by independently promoting vascular 
inﬂ  ammation and pro-coagulability. Genetic susceptibility 
for cardiovascular manifestations of OSA may be mediated 
by gene polymorphisms associated with regulation of 
body weight, lipid metabolism, inﬂ  ammatory response and 
autonomic vascular function.
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